Dublin, April 01, 2026 (GLOBE NEWSWIRE) — The “Proleukin Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts” has been added to ResearchAndMarkets.com’s offering.
The report offers comprehensive insights into market statistics, regional shares, and industry trends, equipping stakeholders with essential information for informed decision-making.
The Proleukin market has demonstrated significant growth in recent years, progressing from $1.24 million in 2025 to a projected $1.32 million in 2026, achieving a CAGR of 6.4%. This growth trend is largely driven by its approval for cystic fibrosis management, proven efficacy in mucus thinning, the rising need for chronic disease treatment, and its adoption in hospital respiratory care leading to improved patient outcomes.
Looking forward, the Proleukin market is anticipated to continue its upward trajectory, expected to reach $1.68 million by 2030 with a sustained CAGR of 6.1%. This robust expansion is attributed to increased diagnosis rates of cystic fibrosis, enhanced patient life expectancy, the growing adoption of homecare therapies, and the emergence of specialty pharmacies, all coupled with ongoing innovations in respiratory therapies. Notable trends include the standardization in cystic fibrosis treatment, long-term usage in mucus clearance therapies, and the integration of home-based nebulized treatments with hospital care.
The escalating prevalence of cancer further propels the Proleukin market. Factors such as an aging population, lifestyle changes, and improved detection methods contribute to this surge. Proleukin serves as a pivotal immunotherapy, leveraging high-dose interleukin-2 to bolster the immune system’s capability against aggressive cancers like metastatic melanoma and renal cell carcinoma. According to the World Health Organization’s February 2024 findings, new cancer cases are expected to skyrocket by 77% by 2050, intensifying the demand for effective therapeutic interventions such as Proleukin.
Further bolstering the market, burgeoning research and development (R&D) activity is pivotal in exploring new indications, enhancing delivery mechanisms, and optimizing efficacy. In a recent report from February 2025, the National Center for Science and Engineering Statistics highlighted a $48 billion surge in U.S. R&D expenditures from 2022 to 2023. This investment underpins advancements in Proleukin’s clinical utility and broadens its reach among patients.
In a significant industry move, Iovance Biotherapeutics acquired Proleukin in May 2023 from Clinigen Limited. This acquisition enhances Iovance’s T-cell immunotherapy platform, aiming to bolster the efficacy of tumor-infiltrating lymphocyte therapies and solidify its position in the competitive oncology market.
Regionally, North America led the Proleukin market in 2025, with Asia-Pacific projected as the fastest-growing region in upcoming years. Tariffs have notably impacted the supply chain within Europe and Asia-Pacific, increasing costs and encouraging local manufacturing strategies.
Reasons to Purchase:
- Gain a global perspective with comprehensive coverage across 16 geographies.
- Evaluate the impact of macroeconomic factors such as geopolitical conflicts, trade policies, tariffs, inflation, interest rate fluctuations, and ongoing regulatory changes.
- Formulate regional and country-specific strategies using localized data.
- Identify key growth segments for investment opportunities.
- Leverage forecast data to outperform competitors by understanding market drivers and trends.
- Conduct end-user analysis to enhance customer understanding.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Assess total addressable market (TAM) and market attractiveness to gauge market potential.
- Enhance presentations with high-quality data and analysis for internal and external use.
- The report includes the latest data updates with an accompanying Excel sheet for easy extraction and analysis, delivered in a user-friendly dashboard format.
Report Scope
Markets Covered: 1) By Type: Injection; Powder; Other Types 2) By Therapeutic Area: Oncology; Immunology; Other Areas 3) By Clinical Indication: Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Other Indications 4) By Application: Hospital; Pharmacy 5) By End-User: Adults; Pediatrics
Companies Mentioned: Novartis Pharmaceuticals Corporation
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five-year historical data with ten-year forecasts.
Data: Market size and growth ratios to related markets, GDP proportions, per capita expenditure data.
Data Segmentation: Historical and forecast data by country and region, competitor market shares, market segments.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $1.32 Million |
| Forecasted Market Value (USD) by 2030 | $1.68 Million |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/gu1cvs
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
